Upsher-Smith Shuffles Portfolio With A Pair Of Deals

Expands Partnership With Appco As Two ‘Dormant’ ANDAs Are Divested

Sawai’s Upsher-Smith business in the US has announced a pair of deals that will see the firm expand an existing partnership with Appco for a “near-term generic product opportunity” as well as divesting two “dormant” ANDAs in favor of a focus on more immediate assets.

Magician shuffle cards
Upsher-Smith is shuffling its portfolio to focus on near-term profit • Source: Shutterstock

Sawai’s US Upsher-Smith business has reshaped its portfolio with a pair of deals that will see the firm add a “near-term” generic product opportunity to an existing partnership with Appco, as well as divesting two dormant abbreviated new drug applications in favor of a focus on near-term assets.

Announcing that it had “expanded its ongoing partnership with Appco Pharma with the addition of a near-term generic product opportunity to its portfolio,” Upsher-Smith said this formed part of a “company-wide effort to grow the company’s

More from Deals

More from Business